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Most acute hepatitis C virus (HCV) infections become chronic and some progress to liver cirrhosis or
hepatocellular carcinoma. Standard therapy involves an interferon (IFN)-a-based regimen, and efficacy of
therapy has been significantly improved by the development of protease inhibitors. However, several issues
remain concerning the injectable form and the side effects of IFN. Here, we report an orally available,
small-molecule type I IFN receptor agonist that directly transduces the IFN signal cascade and stimulates
antiviral gene expression. Like type I IFN, the small-molecule compound induces IFN-stimulated gene (ISG)
expression for antiviral activity in vitro and in vivo in mice, and the ISG induction mechanism is attributed
to a direct interaction between the compound and IFN-a receptor 2, a key molecule of IFN-signaling on the
cell surface. Our study highlights the importance of an orally active IFN-like agent, both as a therapy for
antiviral infections and as a potential IFN substitute.
H
epatitis C virus (HCV) infection affects 170 million people worldwide1, and most acute HCV infections
become chronic, with some progression to liver cirrhosis or hepatocellular carcinoma. HCV has a plus-
strand RNA genome that encodes both structural proteins and the nonstructural (NS) proteins 2, 3, 4A,
4B, 5A and 5B. Current standard therapy against chronic HCV infection includes the use of host factor-targeting
pegylated interferon (PEG-IFN)-a and ribavirin2, which is effective in only 50% of patients chronically infected
with HCV genotype 13. The main causes of this low rate of efficacy may be (i) single-nucleotide polymorphisms
(SNPs) in the upstream region of the IL28B gene and (ii) low compliance with the therapy, which must be
administered subcutaneously. Regarding the first cause—SNPs—the host factors that are important in the early
response to therapy remain unknown. However, recent studies report that genetic variants near IL28B, which
encodes IFN-l3 (interleukin 28B), correlate with the response to treatment of chronic hepatitis C infection using
IFN-a/ribavirin combination therapy4–7. Patients with an rs12979860 SNP genotype of CC are reported to have a
stronger response to IFN therapy (up to an 80% sustained virological response (SVR) rate with the combined
therapy) than those with TC or TT genotypes4. Regarding the lack of compliance, the current therapy using
recombinant IFN is a weekly injectable formulation that is unstable, requires refrigeration, and is expensive and
complex to administer. Furthermore, therapy is often poorly tolerated as a result of the presence of many adverse
effects, including flu-like symptoms, hematological abnormalities and adverse neuropsychiatric events, any of
which may require early discontinuation8. These side effects may result in dose modifications that lead to less-
than-optimal responses.
Recent trends in drug development focus on drugs targeted against viral proteins such as NS 3/4A serine
protease, RNA helicase, NS4B, NS5A, and NS5B RNA-dependent RNA polymerase9. Very recently, two NS3/4A
protease inhibitors, telaprevir and boceprevir, have been approved as new anti-HCV agents. Adding such an
inhibitor to the standard therapy in the ADVANCE10 and the SPRINT-211 trials achieved significantly higher SVR
rates, but the issue still remains that using these inhibitors without injectable IFN possibly yields clinical resist-
ance12. To overcome this problem and alleviate the low compliance outlined above, an orally available IFN would
be valuable because the dosing regimen is less complex.
IFNs induce the expression of a subset of IFN-stimulated genes (ISG)13, some ofwhich show antiviral activity or
are involved in lipid metabolism, apoptosis, protein degradation and inflammation14. IFNs are not only effective
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against HCV infection, but are also essential for innate immunity.
Broadly speaking, type I IFNs (IFN-a and -b) bind to their receptor,
causing the phosphorylation and activation of JAK1 andTyk2, which
is followed by the phosphorylation of signal transducers and activa-
tors of transcription (STATs) and subsequent ISG expression. To
activate the JAK/STAT pathway, IFN-a requires the IFN-a/b recep-
tor, which consists of 2 subunits, IFN-a receptor (IFNAR) 1 and
IFNAR2. These IFNAR subunits together form a heterodimer upon
IFN stimulation. This association of IFNAR2 and IFNAR1 is re-
quired to mediate the antiviral, antiproliferative, and apoptotic
effects of type I IFNs15–17 because the dimerization of IFNARs
induces the phosphorylation of the receptor-associated tyrosine
kinases, JAK1 and Tyk2, and the phosphorylated JAK kinases then
phosphorylate STAT1 and STAT2. In turn, phosphorylated STAT1
and STAT2 bind to IRF9 to form the transcriptional activator IFN-
stimulating gene factor 3 (ISGF3) that induces the expression of a
subset of ISGs13.
Using quantitative high-throughput screening (HTS), we iden-
tified in this study a novel small molecule that acts like IFN by
directly interacting with the type I IFN receptor to drive ISG express-
ion. Our results indicate that oral administration of the small-
molecule IFN agonist stimulates ISG expression in mice, and that
the ISG expression from this small-molecule IFN provides antiviral
activity, indicating that the compoundmay be a potential therapeutic
IFN substitute.
Results
Identification of antiviral small-molecule IFN agonists by high-
throughput chemical library screening. HCV replicon cells, which
were established ten years ago18 using a cell line that expresses the
HCV genotype 1b subgenomic replicon19, possess a luciferase gene as
a reporter optimized for use in a robust HTS system. TheHTS system
provides in-depth analysis of primary screening results, including
detailed information regarding potency, efficacy and structure-
activity relationships. IFNs show strong inhibition using this sys-
tem and have been used as a positive control in the assay. Many
compounds, including HCV protease inhibitors and HCV poly-
merase nucleoside/non-nucleoside analogs, have been assessed and
are being developed for clinical testing. Analysis of data from the
combination of target/counterscreen HTS, data from other assays
measuring cellular toxicity, in vitro sphingolipid biosynthesis
and HCV enzymatic activity (including protease and polymerase)
allowed us to select compounds with potentially novel modes of
action from the primary screen.
A secondary IFN signal assay, using a luciferase reporter gene
which was located downstream of the IFN-stimulated response ele-
ment (ISRE), eliminated assay-related false-positive compounds. Of
the remaining anti-HCV replicon compounds, one of themost active
was an imidazonaphthyridine with the structural formula 8-(1, 3,
4-oxadiazol-2-yl)-2, 4-bis (trifluoromethyl) imidazo [1, 2-a] [1, 8]
naphthyridine (RO4948191, hereinafter RO8191) (Fig. 1a). This
compound strongly suppressed HCV replicon activity at 72 h in a
dose-dependent manner (Fig. 1b, left graph) without inducing host
cell toxicity, as measured by the WST-8 (Fig. 1b, right graph) and
CellTiter-Glo assays (data not shown). The IC50 (50% inhibitory
concentration) of the compound in an anti-HCV replicon assay
was 200 nM. The compound suppressed viral replication within
24 h and showed even more effective inhibition, without cytotoxi-
city, after 7 days (Supplementary Fig. 1). In addition, the HCV RNA
replicon levels significantly decreased after incubation with the com-
pound for 72 h, as determined by real-time reverse transcription
(RT)-polymerase chain reaction (PCR) analysis (Fig. 1c). Immuno-
staining showed that levels of the proteins HCV NS3 and NS4A,
which are localized mainly in the perinuclear region of the replicon
cells, were also reduced after RO8191 treatment for 24 h (Fig. 1d).
This treatment also resulted in the disappearance of viral proteins
such as NS3, NS4A/B, and NS5A/B, as shown by western blot ana-
lysis (Fig. 1e). The luciferase activity of HCV subgenomic genotype 2
replicon cells (JFH1, data not shown) and, surprisingly, the HCV
viral titer of JFH120 in a Huh-7/K4 cell line were also reduced by
RO8191 treatment (Fig. 1f).
RO8191 induces IFN signals, ISGs expression and JAK/STAT
phosphorylation. To clarify whether RO8191 shows inhibitory
activity against another RNA virus, we tested its action in en-
cephalomyocarditis virus (EMCV)-infected A549 cells. RO8191
showed a cell-protective activity against EMCV infection similar to
that of IFN-a (Fig. 2a). Because IFN-a is the most common host cell
factor to exert its antiviral activity against HCV21,22 by inducing ISG
expression13, we compared the gene expression profiles of IFN-a and
RO8191 by conducting a global-scale DNA microarray analysis to
identify genes, especially ISGs23, that were regulated by RO8191. As
expected, RO8191 increased the expression of some ISGs (Supple-
mentary Fig. 2 and Supplementary Table 1). DNA microarray
analysis showed that RO8191 induced the expression of IP-10
(CXCL10), known as an ISG, RO8191 did not induce the genes
encoding inflammatory cytokines and chemokines (Supplementary
Fig. 3a). And, a reporter gene assay was performed using an NF-kB
reporter gene. We transiently transfected the reporter gene to HCV-
naı¨ve HuH-7 cells, and then treated themwith RO8191 or TNF-a. In
Huh-7 cells, NF-kB reporter gene was activated by TNF-a treatment,
but not by RO8191 (Supplementary Fig. 3b). These results indicate
that RO8191 specifically induces the IFN-relevant gene expressions.
Real-time RT-PCR analysis also revealed that RO8191 induced
many ISGs similar to those expressed in IFN-a-treated cells
(Fig. 2b and Supplementary Table 2), suggesting that the antiviral
mechanism of RO8191 depends on ISG expression. In addition to
HCV replicon cells, we tested the compound in several cancer cell
lines and normal human primary hepatocytes (Hc cells). Real-time
RT-PCR analysis showed that RO8191 induced ISG expression in
cultured cell lines and human primary hepatocytes (Supplementary
Table 3 and Supplementary Fig. 4). These results suggest that
RO8191 induces an IFN signal, and that the application in clinical
of RO8191 is not limited to suppressing HCV infection.
As mentioned earlier, type I IFNs phosphorylate JAK kinases and
STAT proteins by inducing a heterodimerization of both IFNAR1
and IFNAR2, and the complexes thus formed transduce signals from
IFN. Since RO8191 induces ISGs in a similar profile to IFN-a, we
examined the phosphorylation of IFN signalingmolecules. Immuno-
blotting analysis was performed to detect phosphorylated tyrosine
(Tyr) and serine (Ser) residues of the STATs and JAK kinases using
cell lysate that was treated with 50,5000 times the HCV replicon
IC50s of RO8191, IFN-a, IFN-b, and IFN-c (type II IFN). The degree
to which both RO8191 and IFN-b phosphorylated STAT1, STAT5,
and STAT6was similar, as shown in Fig. 2c, and the phosphorylation
level of STAT2 by RO8191 was quite similar to that of IFN-a.
Interestingly, STAT3 and JAK1 were more strongly phosphorylated
by RO8191 than by IFN-a, -b, or -c. On the other hand, Tyk2 was
phosphorylated by type I IFNs, but not by IFN-c or RO8191, indi-
cating that Tyk2 is dispensable for RO8191 activity (Fig. 2c). Taken
together, the phosphorylation profile of STAT proteins by RO8191 is
generally similar to that of type I IFNs, and the phosphorylation
profiles of STAT1–3, 5, 6, and JAK1 in HCV replicon cells treated
with RO8191 or type I IFNs suggest a common mechanism that
differs from the mechanism in cells treated with type II IFN.
In addition to imiquimod, an IFN inducer and a Toll-like receptor
(TLR) 7 agonist24, small-molecule ligands recognized by TLRs and
RIG-I–like receptors are known to induce ISG expression by indu-
cing IFN25. The chemical structure of RO8191 is similar to imiqui-
mod so we examined whether RO8191 has a mechanism of activity
like imiquimod. However, imiquimod did not affect HCV replicon
cells (Supplementary Fig. 5a) and, moreover, did not stimulate
www.nature.com/scientificreports
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STAT1 phosphorylation, whereas RO8191 caused prolonged STAT1
activation (for up to 8 h post-treatment; Supplementary Fig. 5b).
Next, RO8191 is actually a small-molecule and we could not exclude
the possibility that the antiviral activity might be induced through
TLRs. To confirm that, we tested ISG induction using Tlr3, 4, 7 and 9
knockout (KO) mouse embryo fibroblasts (MEF)24,26–28. We treated
the MEFs with RO8191 or murine IFN-aA for 8 h and both induced
Oas1b mRNA in wild type and Tlr-KO MEFs (Supplementary Fig.
5c), demonstrating that RO8191 induces ISG expressions indepen-
dently of TLRs. To exclude the possibility that RO8191 acts by indu-
cing type I IFN, we examined its effects in Vero cells that lack the IFN
gene locus29,30. Whereas imiquimod did not show IFN-like effects
in Vero cells, RO8191 and IFN-a induced the ISRE activation
(Supplementary Fig. 5d), indicating that RO8191 acts independently
of the inducing IFN and is quite distinct from imiquimod.
RO8191 exerts antiviral activity dependent on IFNAR2/JAK1,
but is independent of IFNAR1/Tyk2. IFNs require IFN receptor
subunits for their activity, and we hypothesized that RO8191 uses the
IFN receptor to exert anti-HCV activity. To determine the
contributions of IFNAR1 and IFNAR2 toward the anti-HCV
replicon activity of RO8191, we suppressed the expression of these
receptors using specific siRNA and treated the cells with RO8191 or
IFN-a. The knockdown efficiency was determined using RT-PCR in
the HCV replicon cells transfected with each siRNA, as shown in
Supplementary Fig. 6. As expected, a knockdown of each receptor
subunit decreased the antiviral activity of IFN-a (Fig. 3a and b,
Supplementary Fig. 7a and b). IFNAR2 knockdown attenuated the
antiviral activity of RO8191 (Fig. 3b and Supplementary Fig. 7b) but,
interestingly, IFNAR1 knockdown did not change the antiviral
activity (Fig. 3a and Supplementary Fig. 7a), suggesting that
RO8191 is independent of IFNAR1. To address whether IFN-a
receptor contributes to RO8191 signaling, we evaluated RO8191
using Ifnar1-KO MEF cells31. We treated Ifnar1-KO MEFs with 50
mMRO8191 or 1,000 IU/mL ofmurine IFN-aA for 8 h and analyzed
the expression of murine Oas1b mRNA using real-time RT-PCR.
Murine IFN induced murine Oas1b mRNA only in wild type
MEFs, not in Ifnar1-KO MEFs, although RO8191 induced Oas1b
in both wild type and Ifnar1-KO MEFs (Supplementary Fig. 8).
Therefore, RO8191 induces IFN-like activity even in Ifnar1-KO
MEFs.
Since IFNAR2 knockdown reduced RO8191 activity, we focused
on and analyzed the IFNAR2 function using RO8191. First, U5A
cells, which do not respond to IFN-a because of the lack of
Figure 1 | Identification of a small molecule that inhibits HCV replication. (a) The chemical structure of RO8191. (b) After treatment with various
concentrations of RO8191 or 100 IU/mL IFN-a for 72 h, HCV replication levels were examined using a luciferase assay (left graph), and cell viabilities
were determined using a WST-8 assay (right graph). The mean values and their SDs were recorded for treated cells as a percentage of the values for
untreated cells, and the values represent themeans of 3 independent experiments. (c) Total RNAwas extracted fromHCV replicon cells cultured with the
indicated concentration of RO8191 or 100 IU/mL IFN-a for 72 h; HCV RNA levels were analyzed using real-time RT-PCR. The mean values and their
SDs were recorded for treated cells relative to themRNA levels of b-actin, and are shown as a percentage of untreated cells. The values represent themeans
of 3 independent experiments. (d) HCV replicon cells were treated with control medium (left panels) or 10 mM RO8191 (right panels) for 24 h and
immunostained with Hoechst 33452 (blue), anti-NS3 antibody (green), and anti-NS4A antibody (red). The results were then merged (yellow). (e) HCV
replicon cells were treated with the indicated concentrations of RO8191 or 100 IU/mL IFN-a for 72 h. Whole cell lysates were immunoblotted with
antibodies specific to the indicated HCV NS proteins. (f) After infection with the HCV JFH1 strain, Huh-7/K4 cells were treated with the indicated
concentrations of RO8191 for 72 h. Total RNA was extracted, and the HCV RNA levels were analyzed using quantitative real-time RT-PCR.
www.nature.com/scientificreports
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IFNAR2 expression32, were treated with RO8191. Although RO8191
and IFN-a did not induce OAS1 expression in the U5A cells,
IFNAR2-overexpressing U5A cells were successfully complemented,
and this conferred susceptibility to both RO8191 and IFN-a (Fig. 3c
and d). RO8191 also induced the OAS1 gene in HT1080 and 2fTGH
cells, the parental cell lines of U5A cells (Supplementary Table 3,
lowest and second lowest rows). Second, to elucidate whether
RO8191 directly interacts with IFNAR2, we obtained a recombinant
IFNAR2 extracellular domain (ECD) protein (N-terminal half of the
protein, amino acids from Ile27- Lys243). The protein was subjected
to surface plasmon resonance (SPR) spectroscopy using a Biacore
system to directly evaluate the binding activity of the recombinant
protein with its possible ligands, RO8191 and IFN-a. The IFNAR2
ECD protein was fixed on the surface of the CM7 sensor chip by
amine coupling, and PEG-IFN-a2a and RO8191 were injected as
analytes. We comparatively analyzed 0.31 and 0.63 mM of RO8191,
and both concentrations showed similar binding affinities of 480.5
and 484.5 nM, respectively (Fig. 3e), whereas a chemically deriva-
tized compound of RO8191 that cannot inhibit HCV replication did
not bind to IFNAR2 ECD (data not shown). The SPR results were
consistent with 1:1 binding and showed an interaction between
RO8191 and the IFNAR2 ECD protein in a dose-dependent manner,
indicating that the compound and IFNAR2 may directly interact on
the cell surface. In addition to the anti-replicon activity, the
phosphorylation of STAT1 by RO8191 was also repressed by
IFNAR2 knockdown (Fig. 3g), but the knockdown of IFNAR1 did
not inhibit the STAT1 phosphorylation (Fig. 3f), indicating that
RO8191 requires IFNAR2 but not IFNAR1 to achieve activity.
Similarly, the knockdown of JAK1 attenuated the activity of
RO8191 and IFN-a (Fig. 4a and Supplementary Fig. 9a), while, in
contrast, Tyk2 and JAK2 were not required for RO8191 activity
(Fig. 4b, Supplementary Fig. 9b and c). The phosphorylation of
STAT1 by RO8191 was also inhibited by a knockdown of JAK1
(Supplementary Fig. 10a), but not by a knockdown of Tyk2
(Supplementary Fig. 10b), indicating JAK1 essentiality for the anti-
viral activity of RO8191. To confirm Tyk2-independency, we used
U1A (Tyk2-deficient) cells and the parental cell, 2fTGH33, and
treated them with 50 mM RO8191 or 100 IU/mL IFN-a for 8 h to
analyze the expression ofOAS1. As expected from previous reports34,
IFN-a induced the OAS1 expression only in 2fTGH cells but not in
U1A cells; however, RO8191 induced the expression in both 2fTGH
and U1A cells significantly (Supplementary Fig. 11). Thus, RO8191
activates ISGs in a JAK1-dependent and Tyk2-independent manner;
on the other hand, IFN-a depends on both factors. Next, we con-
ducted a knockdown of the transcription factors related to type I
IFNs activity, STAT1, STAT2 and IRF-9, to clarify whether RO8191
required these factors for antiviral activity. As expected, STAT1-
siRNAs partially blocked IFN-c activity (Supplementary Fig. 9d),
Figure 2 | RO8191 activates JAK/STAT and induces IFN-like signals. (a) The cytopathic effect of EMCV infection was inhibited by the indicated
concentrations of RO8191 or IFN-a. Viable cells were stained with crystal violet. The data shown are the mean values and SDs based on experiments
performed in quadruplicate. (b) ISG expression levels were measured using real-time RT-PCR. Total RNA was extracted from HCV replicon cells
cultured in the presence of 50 mMRO8191 or 100 IU/mL IFN-a for 2 or 8 h and known ISGs were analyzed. Asterisk indicates 2-h treatment with agents.
The values shown are the mean fold change induction compared to the mRNA level of human b-actin and the fold change induction compared to
untreated cells. (c)HCV replicon cells were treatedwith various concentrations of the indicated agents for 15 min. Total lysates were immunoblottedwith
antibodies to STATs or JAK kinases. The HCV replicon IC50 of IFN-a was 0.4 IU/mL, that of IFN-b was 3 IU/mL, and that of IFN-c was 0.3 ng/mL.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 259 | DOI: 10.1038/srep00259 4
which is mediated by STAT1 homodimers35. STAT1 was significantly
phosphorylated by both RO8191 and IFN-a (Fig. 2c); however, the
STAT1 knockdown affected neither RO8191 nor IFN-a activity
(Fig. 4c and Supplementary Fig. 9d). We also analyzed the impact
of STAT1 knockdown on OAS1 induction by RO8191, and found
OAS1 induction by RO8191 was inhibited (Supplementary Fig. 12).
STAT2 and IRF9 knockdown attenuated the inhibitory activity of both
RO8191 and IFN-a (Fig. 4d and e and Supplementary Fig. 9e and f).
In summary, RO8191 only binds to IFNAR2 and activates JAK1,
STATs, and IRF9, thereby exhibiting type I IFN-like activity (Fig. 4f).
RO8191, an IFNAR2 agonist, stimulates IFN signals in mice. To
evaluate whether RO8191 could be a clinical lead for drug
development, we studied the effects of RO8191 on IFN signaling in
mice. The compound or vehicle was orally administered tomice and,
24 h after treatment, the liver was removed and examined. The
antiviral genes Oas1b, Mx1, and Pkr were significantly induced in
the livers of mice treated with RO8191 (Table 1). As expected, gene
homologs that were induced in the livers of HCV patients treated
with PEG-IFN-a2b36 were also induced in mouse liver (Ifit3, Isg15,
Mda5, Rig-I, Socs1 and Stat1; Table 1). In addition, genes that had
previously been reported to be induced by IFN-b in mouse liver37
were also induced in the livers of RO8191-treated mice (Cxcl10, Ifit3,
Isg15, Socs1 and Usp18; Table 1,). We also measured inflammatory
cytokine and chemokine expressions, and RO8191 did not
significantly induce the expression of these genes (Supplementary
Table 4). To evaluate anti-HCV activity of RO8191 in vivo, RO8191
was orally administered to HCV-infected humanized liver mice38.
The results of this humanized liver mice study showed that
RO8191 reduced HCV titer in vivo (Supplementary Fig. 13). These
data show that RO8191 stimulates IFN signaling and is an orally
available agent in mice.
Discussion
In this study, we identified a small-molecule IFN receptor agonist,
RO8191, by quantitative HTS of a chemical library. This com-
pound showed antiviral activity against both HCV and EMCV,
suggesting a broad spectrum of target viruses. To learn more
about the possible mechanism of action of IFN signal induction
by RO8191, we investigated IFN-induced signaling and ISG
induction by the small-molecule compound in vitro and in vivo.
A comparison of microarray expression profiles in HCV replicon
cells stimulated by IFN-a or RO8191 indicates that the IFN signal
was induced not only by IFNs, but also by the small-molecule
compound (Fig. 2b and Supplementary Fig. 2). Thus, this com-
pound is an IFN-a-like small molecule, but the mechanism of the
RO8191 antiviral activity remained unknown. Therefore, we
examined the JAK/STAT activation pathway, which includes key
players in the IFN signaling cascade.
Like type I IFNs, RO8191 significantly phosphorylates and acti-
vates STATs, in particular, STAT1 and STAT2 (Fig. 2c). Intriguingly,
in HCV replicon cells, STAT1 expression knockdown did not affect
the antiviral activity of RO8191 or IFN-a, although IFN-c activity
was inhibited (Fig. 4c). These data suggest that, in addition to indu-
cing similar gene expression, RO8191 and IFN-a exhibit similar
STAT phosphorylation profiles. Although RO8191- and IFN-a-
mediated antiviral activity remained constant when STAT1 express-
ion was reduced, this could be because IFN-a signaling in HuH-7
cells requires minimal amounts of STAT1 protein and STAT1
expression was not reduced below such a critical threshold by
siRNA in our system. In contrast, the inhibitory activity of RO8191
was attenuated to the same extent as that of IFN-a when the express-
ion of other components of ISGF3 (STAT2 and IRF-9) were reduced
by siRNA (Fig. 4d and e). Incidentally, STAT1 siRNA did not attenu-
ate RO8191 or IFN activity in EMCV-infected A549 cells (supple-
mentary Fig.14), which supports the notion that STAT2 is an
essential component of type I IFN signaling39. Type I IFN stimulates
the formation of other STAT-containing complexes, including
STAT1:STAT1, STAT3:STAT3 and STAT5:STAT5 homodimers, as
well as STAT1:STAT3 and STAT2:STAT6 heterodimers40–42. Like IFN,
RO8191 induced the phosphorylation of STAT1 and STAT2, which
function as a gateway to the type I IFN signal cascade, and stimulated
the phosphorylation of STAT3, 5 and 6. Another possible cause for the
fact that STAT1 knockdown did not show any effect on RO8191
inhibition could be compensation by these IFN signaling-stimulated
STAT complexes. This finding matches the recent report by Perry
et al. on the STAT dependency of IFN activity against Dengue virus,
that belongs to flavivirus43. They showed that STAT2 mediates IFN
antiviral signals even in STAT1 KO cells and they discussed the pos-
sibility that other STAT family proteins would compensate for STAT1
deficiency. In summary, with regards to the activation of transcription
factors and ISG expression, RO8191 and IFN-a mediate the same
pathway.
IFNs activate JAK kinases via IFN receptors to induce STAT phos-
phorylation. RO8191 robustly phosphorylated JAK1 (Fig. 2c) in
comparison with IFN-a or -b and therefore we focused on
IFNAR2 (a JAK1-binding subunit of the type I IFN receptor). As
with IFN-a, the activity of RO8191 was inhibited by IFNAR2 knock-
down (Fig. 3b). The suggestion that IFNAR2 is an essential molecule
for RO8191-induced signal transduction is supported by the fact that
an IFNAR2-deficient cell line, U5A, did not respond to RO8191.
Furthermore, after IFNAR2 expression had been complemented in
the U5A cells, ISG induction by both RO8191 and IFN-a recovered
(Fig. 3c and d). The mechanism was directly explained by SPR spec-
troscopy, which showed an interaction between RO8191 and the
IFNAR2 ECD (Fig. 3e). RO8191 strikingly phosphorylates the
IFNAR2-associated kinase JAK1, when compared to other IFN-
treated cell lysates (Fig. 2c). JAK1 siRNA expression inhibited
RO8191 activity (Fig. 4a), indicating that JAK1 is also an essential
molecule for RO8191 activity. Interestingly, RO8191 activity remains
static when IFNAR1 expression is knocked down, unlike IFN-a
activity (Fig. 3a). The IFNAR1-binding-kinase Tyk2 is not required
for RO8191 activity (Fig. 4b) and Tyk2 was not phosphorylated
(Fig. 2c) by RO8191. Also, RO8191 induced its signal even in the
Ifnar1 KOMEF and the Tyk2-deficient cell line (Supplementary Fig.
Table 1 | ISG expression in the livers of RO8191 treated mice. ISG
expression levels were measured using real-time RT-PCR. Values
are listed relative to the mRNA levels of rodent Gapdh and repres-
ent the mean fold change induction compared to vehicle-
administered mice. Twenty-four hours after oral administration
of 30 mg/kg RO8191 or vehicle (including 10% dimethyl sulf-
oxide and 10% Cremophor) to mice, total RNA was extracted
from the mouse livers, and the mRNA levels of murine ISGs were
measured using real-time RT-PCR. The data shown are the means
and SDs of 4 mice per group. The data were statistically analyzed
using Student’s t-test, and differences were considered significant
at p values , 0.05
Gene Entrez ID Fold change 6 SD p-value
murine Oas1 NM_001083925 3.0 6 0.72 0.003
murine Mx1 NM_010846 2.1 6 0.15 0.0003
murine Pkr NM_011163 1.4 6 0.21 0.009
murine Cxcl10 NM_021274 1.7 6 0.63 0.097
murine Ifit3 NM_010501 2.5 6 0.48 0.001
murine Isg15 NM_015783 2.3 6 0.41 0.002
murine Mda5 NM_027835 1.6 6 0.22 0.003
murine Rig-i NM_172689 2.1 6 0.16 0.00003
murine Socs1 NM_009896 2.6 6 1.04 0.057
murine Stat1 NM_009283 1.8 6 0.21 0.001
murine Usp18 NM_011909 2.6 6 0.69 0.017
www.nature.com/scientificreports
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8 and 11). IFN-a induces a signal via IFNAR1/Tyk2 and IFNAR2/
JAK1 although RO8191 and IFN-a induce common ISGs (Fig. 2b
and Supplementary Fig. 2), RO8191 activity was dependent only on
IFNAR2.
We therefore propose a novel model of the induction of IFN-like
signal transduction by this small molecule (Fig. 4f). So far, the
IFNAR2 homodimer has been suggested to play various roles in
IFN signal transduction34,44,45, and RO8191 would induce the ISG
expression via such IFNAR2 homodimer. For type I IFN, both
IFNAR1 and IFNAR2 cooperate and induce phosphorylation of
STATs via JAK1 and Tyk2. Conversely, for RO8191, IFNAR2 alone,
as a homodimer, activates JAK1 phosphorylation and subsequent
STATs activation. Experiments using siRNA and deficient cells have
also shown that IFNAR1 and Tyk2 were not required to induce
antiviral activity in the RO8191 compound pathway. These findings
suggest a novel aspect of the IFN signaling pathway that may con-
tribute to the understanding of other molecular signaling in IFN
pathways.
RO8191 is a small molecule whose oral administration is feasible
and effective in amurinemodel (Table 1 and Supplementary Fig. 13).
In the chimericmice study, the anti-HCV effect of RO8191 and PEG-
IFNwas similar in that they both showed strong activity at day 1 after
treatment with subsequent weak suppression of HCV replication
possibly due to the immunodeficiency of chimeric mice. Further
development of RO8191 by using rational chemical modifications
is therefore required to produce more potent molecules for testing as
an antiviral molecule which will substitute current recombinant IFN.
Although RO8191 has the potential to cause IFN-like adverse effects,
further development of the small-molecule agonist offers the advan-
tages of inexpensive production cost, convenient oral administra-
tion, dose-control to reduce some adverse effects, and potentially
increased activity versus current recombinant IFNs.
Whereas oral NS3 protease inhibitors in monotherapy develop-
ment yield resistant viruses46,47, these protease inhibitors show a
significantly high rate of SVR when combined with PEG-IFN10,11
and a NS5B polymerase inhibitor also shows additive efficacy in
combination with PEG-IFN48. In addition to the results of the in vivo
study, we found that RO8191 induced ISGs at a level similar to IFN-a
in human primary hepatocytes (Supplementary Fig. 4); we therefore
expect that RO8191 will show IFN-like activity in clinical use. As an
Figure 3 | RO8191 requires and binds IFNAR2. (a, b) The anti-HCV replicon activity of RO8191 was attenuated by knockdown of IFNAR2 (b), but not
IFNAR1 (a). Inhibition of HCV replicon replication by each agent is shown (the mean and SD from 3 experiments). The HCV replicon cells were
transfected with 50 nMof the indicated siRNAs (blue, red, and yellow bars). Forty-eight hours after transfection, theHCV replicon cells were treated with
1.5 mMRO8191 or 3 IU/mL IFN-a for 24 h. Twenty-four hours after treatment with each agent, the replication levels of HCVRNAwere analyzed using a
luciferase assay. (c, d) U5A cells that lack IFNAR2 were transfected with either an empty vector or a vector expressing the IFNAR2 gene. (c) Forty-eight
hours after transfection, the cells were treated with 50 mM RO8191 (red bars) or 100 IU/mL IFN-a (yellow bars). After an additional 8 h of incubation,
total RNA was extracted from the U5A cells, and the OAS1 mRNA level was measured using real-time RT-PCR. The values shown are relative to the
mRNA level of human b-actin. (d) Forty-eight hours after transfection, the cells were lysed, and the whole cell lysates were immunoblotted with the
indicated antibodies. (e) Real-time kinetic SPR analysis of the binding of RO8191 to the IFNAR2 ECD (red and blue lines). The results are consistent with
1:1 binding. PEG-IFN-a2awas also injected as a positive interacting control for IFNAR2 (black line, KD: 30 nM). (f, g) The phosphorylation of STAT1was
attenuated by a knockdown of IFNAR2 (g) but not IFNAR1 (f). The HCV replicon cells were transfected with the indicated siRNAs (10 nM). Forty-eight
hours after transfection, the cells were treated for 15 min with 10 mM RO8191 or 200 IU/mL IFN-a. The total lysates were subjected to western blot
analysis to analyze the phosphorylated and total protein levels of STAT1. The data were statistically analyzed using Student’s t-test.
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alternative strategy to protease/polymerase inhibitors with PEG-
IFN, the combined use of these direct-acting antiviral agents with
RO8191 in a new oral regimen may help overcome some of the
delivery problems associated with current IFNs. SVR rates of indivi-
duals infected with HCV genotype 1 have increased from 5-20%with
IFN monotherapy and up to 50% with a combination of IFN and
ribavirin. However, the refractory patients in this therapy constitute
an unmet medical need. Thus, the development of a novel IFN
receptor agonist, used alone or in combination with direct-acting
antiviral drugs, will add a new milestone to the treatment of chronic
hepatitis C. In addition to HCV infection, type I IFNs have been
approved for the treatment of multiple clinical conditions, including
hairy cell leukemia, malignant melanoma, AIDS-related Kaposi’s
sarcoma, multiple sclerosis, and chronic hepatitis B49. Thus, R08191
shows strong potential as a lead compound for IFN substitutes.
Methods
Cell culture, mice, and reagents. The #Huh7/3-1 cell line, which expresses HCV
replicons, was a kind gift from F. Hoffmann-La Roche. The cells were cultured in
0.5 mg/mLG418-containingDulbecco’smodified Eagle’smedium (DMEM,GIBCO)
supplemented with 10% fetal bovine serum (FBS, HyClone). The replicon construct
was derived from pFK-I377neo/NS3-39/WT, as previously reported19. Hc cells (DS
Pharma Biomedical) were cultured in CSC Complete Defined Serum-Free Medium
(Cell Systems Corporation) supplemented with SF4ZR-500-D Rocket Fuel. Tlr KO
MEFswere purchased fromOrientalBioService, Inc. Ifnar1KOMEFwas kindly gifted
by Prof. Takaoka. 2fTGH, and U1A and U5A cells were kindly gifted by Prof. Stark.
Culture conditions for the other cell lines are shown in Supplementary Table 5. Six-
week-old C57BL/6J mice were obtained from Charles River Laboratories. Chimeric
mice harboring a functional human liver cell xenograft were purchased from
PhoenixBio. The protocol was reviewed by the Institutional Animal Care and Use
Committee of Chugai Pharmaceutical Co., Ltd. and all mouse experiments were
performed in accordance with the Guidelines for the Accommodation and Care of
Laboratory Animals promulgated in Chugai Pharmaceutical Co., Ltd. Recombinant
human IFN-a2a was a kind gift from F. Hoffmann-La Roche. Recombinant murine
IFN-aA and human IFN-b1a were purchased from PBL Interferon Source.
Recombinant TNF-a and IFN-cwere purchased from R&D Systems. Imiquimod was
purchased from LKT Laboratories. JAK inhibitor I was purchased from Merck.
Luciferase assay. Luciferase activity was quantified using the Steady-Glo Luciferase
assay system (Promega) and the EnVision 2013 Multilabel Reader (PerkinElmer).
WST-8 assay.The viability of drug-treatedHuh-7 cells was determined using aWST-
8 cell counting kit (Dojin Laboratories).
Real-time RT-PCR.Total RNAwas extracted using Rneasy (Qiagen), and cDNAwas
synthesized using a Transcriptor First Strand cDNA Synthesis Kit (Roche Applied
Science). Gene expression was measured using the LightCycler 480 System and
LightCycler 480 Probes Master (Roche Applied Science). The amplification used 50
cycles of: 95uC for 5 min, 95uC for 10 s, and 60uC for 30 s. Human b-actin or rodent
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Applied Biosystems)
expression was used as the endogenous reference for each sample. Primers and
TaqMan probes for genes were designed using the Universal Probe Library Assay
Design Center (Roche Applied Science; Supplementary Table 6). The probes used
were from the Roche Universal Probe Library (Roche Applied Science). The samples
Figure 4 | RO8191 activates a novel IFN-like pathway. (a–e) The inhibition of HCV replicon replications by each agent is shown (mean and SD). The
HCV replicon cells were transfectedwith 50 nMof the indicated siRNAs (blue, red, and yellow bars). (a, b) The anti-HCV replicon activity of RO8191was
reduced by knockdown of JAK1 (a) but not Tyk2 (b). Forty-eight hours after transfection, the HCV replicon cells were treated with 1.5 mM RO8191 or
3 IU/mL IFN-a. Twenty-four hours after treatment with each agent, the replication levels of HCV RNA were analyzed using a luciferase assay. (c–e) The
anti-HCV replicon activity of RO8191 was reduced by knockdowns of STAT2 (d) and IRF9 (e), but not STAT1 (c). Forty-eight hours after transfection,
the HCV replicon cells were treated with 1.5 mMRO8191, 3 IU/mL IFN-a, or 50 ng/mL IFN-c. Twenty-four hours after treatment, the replication levels
of HCV RNA were analyzed using a luciferase assay. (f) A schematic showing the pathways of RO8191 and IFN-a. The data were statistically analyzed
using Student’s t-test, and differences were considered significant at p values , 0.05.
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were run in triplicate for each target gene, and each reference gene was used as an
internal control.
Western blotting and immunostaining. Cells were lysed in CelLytic M Cell Lysis
Reagent (Sigma-Aldrich) containing Protease Inhibitor Cocktail (Sigma-Aldrich)
and PhosSTOP (Roche Applied Science). Rabbit polyclonal antibodies against
STAT1, STAT3, STAT6, pY701-STAT1, pY690-STAT2, pY705-STAT3, pS727-
STAT3, pY694-STAT5, pY641-STAT6, pY1022/1023-JAK1, and pY1054/1055-Tyk2
were purchased fromCell Signaling Technology. Rabbit polyclonal antibodies against
actin, STAT2 and STAT5were purchased from Santa Cruz Biotechnology. Anti-Tyk2
rabbit polyclonal antibody was purchased from Upstate. Anti-IFNAR1 mouse
monoclonal (MAB245) and anti-IFNAR2 sheep polyclonal antibodies were
purchased from R&D Systems. Anti-NS3, anti-NS5A, and anti-NS5B rabbit
polyclonal antibodies were a kind gift from F. Hoffmann-La Roche. Anti-NS4A and
anti-NS4B mouse monoclonal antibodies were a kind gift from the Tokyo
Metropolitan Institute of Medical Science. Proteins were detected using the Odyssey
Infrared Imaging System (LI-COR). For immunostaining analysis, the cells were fixed
on a 35-mm glass-based dish (Iwaki) with 4% paraformaldehyde, blocked using 5%
fetal bovine serum in phosphate-buffered saline, and then incubated with anti-NS3
and anti-NS4A antibodies. The cells were then washed and incubated with Alexa488-
labeled anti-rabbit IgG andAlexa568-labeled anti-mouse IgG (Molecular Probes) and
analyzed using confocal laser microscopy.
JFH-1 antiviral assay. A cured K4 cell line derived from HuH-7 HCV replicon cells
was maintained in DMEM supplemented with 10% fetal calf serum (FCS), high-
glucose nonessential amino acids, and HEPES (Invitrogen). The JFH-1/K4 cell line,
whichwas persistently infected with theHCV JFH-1 strain, wasmaintained under the
same conditions as the cured K4 cell line. For the anti-HCV assay of JFH-1/K4 cells
persistently infected with the JFH-1 strain, JFH-1/K4 cells were seeded in a 24-well
tissue culture plate containing DMEM supplemented with 10% FCS, high-glucose
nonessential amino acids, andHEPES (Invitrogen). After overnight incubation, serial
dilutions of reagent in growth medium were added. After 72 h, total RNA was
purified from the JFH-1/K4 cells using Isogene (Nippon Gene). HCV-RNA was
quantified by real-time PCR as previously reported50.
EMCV cytopathic effect assay. This assay was performed on A549 cells seeded in a
96-well tissue culture plate containing DMEM supplemented with 10% FBS. After
overnight incubation, the indicated concentrations of each reagent were added to the
growth medium. After 12 h, 100 TCID50/mL EMCV was added, and after another
48 h, viable cells were stained with 0.5% crystal violet. RNAi experiment using EMCV
was also performed on A549 cells seeded in a 96-well tissue culture plate containing
DMEM supplemented with 10% FBS. We transfected STAT1- or STAT2-siRNA to
A549 cells, and after 72 h we infected EMCV to the cells and treated them with 1 mM
RO8191 or 2 IU/mL IFN. After additional 48 h incubation, we evaluated the cell
viability by staining with crystal violet.
GeneChip and data analysis. Total RNA was extracted from 107 HCV replicon cells
cultured for 8 h in the presence of 2 mM RO8191 or 4 IU/mL IFN-a with TRIzol
Reagent (Invitrogen). Reverse transcription, RNA labeling (5 mg of total RNA),
hybridization to Human Genome U133 Plus 2.0 Arrays (Affymetrix), and scanning
were performed according to the manufacturer’s instructions (Affymetrix, http://
www.affymetrix.com). GC-RMA (GeneChip Robust Microarray Analysis)
algorithms were used to generate scaled gene expression values. The fold change
compared to untreated cells was calculated, and probe sets were selected for genes that
were at least 2.0-fold upregulated in RO8191- and IFN-a-treated cells relative to the
control cells.
RNA interference. For all double-stranded RNAs, ON-TARGET Plus siRNA
reagents (Dharmacon) were used (Supplementary Table 7). The siRNAs were
transiently transfected using Lipofectamine RNAiMAX Transfection reagent
(Invitrogen) according to the manufacturer’s protocols for reverse transfection.
Plasmids and transfection. ISRE and NF-kB reporter gene were purchased from
Clontech. IFNAR2 was cloned into a pCOS2 vector51 harboring the EF1a promoter.
Plasmids were transfected using FuGENE HD (Roche Applied Science) according to
the manufacturer’s instructions.
SPR measurements. SPR binding studies were performed using a Biacore T100.
Recombinant IFNAR2 ECD protein was purchased from R&D Systems. The protein
(1 mg/mL) was diluted 1:20 with 10 mM sodium acetate buffer (pH 5.0) and mixed
with 2 mMRO8191 for stabilization of the binding site. The mixture was immobilized
on a Series S sensor chip CM7 using amine coupling. RO8191 and PEG-IFN-a2a
(Chugai Pharmaceutical) were injected onto the sensor chip at a flow rate of 0.03
mL/min. Response curves were generated by subtraction of the background signal
generated simultaneously on a control flow cell. Kinetic parameters were obtained by
global fitting of the sensorgrams to a 1:1 model using Biacore T100 Evaluation
Software, version 2.0.1.
Humanized liver mice study. The chimeric mice were generated by transplanting
human primary hepatocytes into severe combined immunodeficient (SCID) mice
carrying the urokinase plasminogen activator transgene controlled by an albumin
promoter38. The chimeric mice used in this study were applied from Inoue et al.52, and
had a high substitution rate of human hepatocytes. Six weeks after hepatocyte
transplantation, patient serum containing 106 copies of HCV genotype 1b was
intravenously injected into eachmouse. HCV titer reached approximately 108 copies/
mL and was stable after 4 weeks of HCV injection and persistently infected for 12
weeks. Here, we used mice after 5 weeks post infection and tested for 2 weeks. The
mice were treated for 14 days with RO8191 30 mg/kg/day orally or PEG-IFN-a2a 30
mg/kg subcutaneously twice weekly. HCV RNA in serum was extracted using the acid
guanidinium-phenol-chloroform method. Quantification of HCV RNA was
performed using real-time RT-PCR based on TaqMan chemistry, as described50.
HCV inoculations, drug administration, blood collection, and killing were performed
under ether anesthesia. Blood samples were taken from the orbital vein and sera were
immediately isolated. The protocols for animal experiments were approved by the
local ethics committee. The animals received humane care according to NIH
guidelines. Patients gave written informed consent before sampling.
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